Charles Schwab Investment Management Inc. Has $10.60 Million Holdings in Collegium Pharmaceutical, Inc. $COLL

Charles Schwab Investment Management Inc. cut its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 355,259 shares of the specialty pharmaceutical company’s stock after selling 12,147 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.11% of Collegium Pharmaceutical worth $10,604,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. MetLife Investment Management LLC increased its position in shares of Collegium Pharmaceutical by 8.5% during the fourth quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company’s stock worth $573,000 after buying an additional 1,558 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of Collegium Pharmaceutical during the first quarter worth $244,000. Janney Montgomery Scott LLC acquired a new stake in shares of Collegium Pharmaceutical during the first quarter worth $439,000. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 8,947.4% during the first quarter. GAMMA Investing LLC now owns 17,552 shares of the specialty pharmaceutical company’s stock worth $524,000 after buying an additional 17,358 shares during the period. Finally, Millennium Management LLC increased its position in shares of Collegium Pharmaceutical by 38.8% during the fourth quarter. Millennium Management LLC now owns 185,918 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after buying an additional 51,972 shares during the period.

Analyst Ratings Changes

COLL has been the subject of several recent analyst reports. Piper Sandler reiterated a “neutral” rating and set a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, HC Wainwright upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price target for the company in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Buy” and a consensus target price of $42.33.

Insider Activity

In other news, Director Gino Santini sold 5,405 shares of Collegium Pharmaceutical stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $37.19, for a total transaction of $201,011.95. Following the completion of the transaction, the director directly owned 95,042 shares in the company, valued at $3,534,611.98. This trade represents a 5.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Dreyer sold 16,389 shares of Collegium Pharmaceutical stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $38.21, for a total transaction of $626,223.69. Following the transaction, the executive vice president owned 103,613 shares of the company’s stock, valued at $3,959,052.73. This represents a 13.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,915 shares of company stock worth $1,614,825 over the last three months. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Stock Down 1.0%

Shares of NASDAQ COLL opened at $39.11 on Monday. The stock has a market capitalization of $1.23 billion, a P/E ratio of 37.61 and a beta of 0.68. The company has a 50-day moving average price of $32.42 and a 200-day moving average price of $30.04. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10.

Collegium Pharmaceutical declared that its Board of Directors has initiated a share repurchase plan on Monday, July 7th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.